Albert David Limited has informed the Exchange about change in Management by appointment of Mr. Amit Mahla as the Chief Executive officer w.e.f 12.05.2026.
ALBERTDAVD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.1 pts less than Nifty Microcap 250 and 9.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Albert David Limited announced the appointment of Mr. Amit Mahla as Chief Executive Officer (CEO) effective May 12, 2026, following the resignation of Mr. Umesh Manohar Kunte from the post of Managing Director & CEO w.e.f. December 18, 2025. The company also reported audited financial results for FY2026 showing total income of Rs. 34,105.14 Lakhs, a significant decline from Rs. 37,534.87 Lakhs in FY2025, with the company reporting a net loss of Rs. 149.47 Lakhs compared to a profit of Rs. 1,720.08 Lakhs in the previous year. The Board recommended a final dividend of Rs. 5 per share (50% on Rs. 10 face value), subject to shareholder approval at the 87th AGM scheduled for August 6, 2026. Internal auditors PwC and cost auditors S. Gupta & Co. were reappointed for FY2026-27.
The appointment of a new CEO with extensive pharma industry experience (28+ years at companies like Cipla, Sun Pharma, JB Pharma) may provide positive signals for business turnaround given the company's significant profit decline. The dividend declaration maintains shareholder returns despite challenging financial performance.